Locations:
SearchAdvertisement
FDA-approved therapy offers promise for patients with castrate-resistant prostate cancer
Cleveland Clinic researchers explore enterprise-wide testing registry to investigate
Cleveland Clinic-led study lays groundwork for more personalized treatments
What's driving tumor progression is the key, says Nima Sharifi, MD
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
One step closer to identifying patients predisposed to treatment-resistant prostate cancer
Research links testosterone-related genetic mutation to prostate cancer outcomes
Advertisement
Advertisement